Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...131132133134135136137138139140141...10651066»
  • ||||||||||  ANV419 / Anaveon
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Monotherapy:  A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) (clinicaltrials.gov) -  Aug 14, 2023   
    P1,  N=4, Terminated, 
    N=52 --> 4 | Trial completion date: Mar 2025 --> Jul 2023 | Recruiting --> Terminated | Trial primary completion date: Sep 2024 --> Jul 2023; The study was ended due to a lack of recruitment
  • ||||||||||  CYP-001 / Cynata Therap
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy:  A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD (clinicaltrials.gov) -  Aug 14, 2023   
    P2,  N=60, Recruiting, 
    N=52 --> 4 | Trial completion date: Mar 2025 --> Jul 2023 | Recruiting --> Terminated | Trial primary completion date: Sep 2024 --> Jul 2023; The study was ended due to a lack of recruitment Not yet recruiting --> Recruiting | Trial completion date: Mar 2026 --> Dec 2026 | Initiation date: May 2023 --> Aug 2023 | Trial primary completion date: Jun 2024 --> Apr 2025
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Weak acid-initiated slow release of Dexamethasone from hydrogel to treat orbital inflammation. (Pubmed Central) -  Aug 13, 2023   
    Additionally, Gel Dex/K mitigated the degree of tissue fibrosis and fatty infiltration by reducing the development of local inflammation in the orbit. Our research results indicate that Gel Dex/K could more efficiently achieve responsive drug release in orbit, providing an innovative method for treating orbital inflammation.
  • ||||||||||  Darzalex (daratumumab) / J&J
    De Novo Multiple Myeloma in a Patient With Transthyretin Amyloid Cardiomyopathy (Zone 4, Science and Technology Hall, Level 2) -  Aug 12, 2023 - Abstract #AHA2023AHA_5867;    
    In patients who are found to have monoclonal gammopathy, an endomyocardial biopsy is crucial to evaluate for amyloid cardiomyopathy. These patients should also be monitored for the progression to multiple myeloma.
  • ||||||||||  lenalidomide / Generic mfg.
    Lenalidomide Associated Coronary Thrombosis (Zone 4, Science and Technology Hall, Level 2) -  Aug 12, 2023 - Abstract #AHA2023AHA_4679;    
    IMiDs have improved outcomes in MM patients, at a small expense of increased venous, and less commonly arterial, thrombosis. Patients should be monitored closely, preferably under the care of an experienced cardiooncologist, with strict control of their cardiac risk factors and consideration of antiplatelet therapy to avoid potential coronary thrombosis.
  • ||||||||||  hydrocortisone / Generic mfg., hydroxocobalamin (vit B12) / Generic mfg.
    Review, Journal:  Vasoplegia: A Review. (Pubmed Central) -  Aug 11, 2023   
    This review expands upon the different vasopressors used in management of vasoplegia, including catecholamines such as norepinephrine, dopamine, epinephrine, phenylephrine, and other agents including vasopressin, methylene blue, angiotensin II, hydroxocobalamin, vitamin C, thiamine, and corticosteroids (ie, hydrocortisone). It also emphasizes the importance of conducting further research and making advancements in treatment regimens for vasoplegia.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Journal:  Deep intracochlear injection of triamcinolone-acetonide with an inner ear catheter in patients with residual hearing. (Pubmed Central) -  Aug 11, 2023   
    No difference in residual hearing loss was found when comparing application of triamcinolone-acetonide using an inner ear catheter prior to the insertion of a FLEX28 electrode array to the use of the FLEX28 electrode array without the catheter. Thus, we conclude that application of drugs to the cochlea with an inner ear catheter could be a feasible approach in patients with residual hearing.
  • ||||||||||  progesterone / Generic mfg., hydrocortisone / Generic mfg.
    Review, Journal:  Mineralocorticoid replacement therapy in salt-wasting congenital adrenal hyperplasia. (Pubmed Central) -  Aug 11, 2023   
    In this review, we explain the role and function of the mineralocorticoid receptor, its ligands and inhibitors and its relevance for the therapy of patients with SW-CAH. We performed an extensive literature search and present data on mineralocorticoid therapy in SW-CAH patients as well as clinical advice how to monitor and optimise mineralocorticoid replacement therapy.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal, Surgery:  Nd:YAG laser therapy on postoperative pain, swelling, and trismus after mandibular third molar surgery: a randomized double-blinded clinical study. (Pubmed Central) -  Aug 9, 2023   
    After surgery, the Nd group was irradiated by the Nd:YAG laser in very long-pulsed mode (VLP, pulse duration 1 ms, 20 Hz, 4 W, R21-C3) in 6 regions of the extraction socket with a total energy of 300 J. For the medication group, dexamethasone 0.75 mg and loxoprofen 60 mg were prescribed immediately and every 12 h thereafter for 3 days...There was no significant difference in swelling or trismus among the three groups (p > 0.05). NdLT is an effective approach to improve complications after M3 surgery.
  • ||||||||||  ABBV-319 / AbbVie
    ABBV-319: A First-In-Class Glucocorticoid Receptor Modulator (GRM) Agonist ADC for the Treatment of B-cell Malignancies () -  Aug 9, 2023 - Abstract #ADCUSA2023ADC_USA_89;    
    The recovery of vision with restoration of photoreceptor layer also shows the nature of the disease to recover with early intervention despite a negative anti-retinal antibody test but with features highly suggestive of npAIR. ABBV-319 is a first-in-class oncology multi-modal ADC with a potent GRM steroid payload; The ADC targets CD19 a clinically validated target with high expression across B-cell malignancies; ABBV-319 has three mechanisms-of-action (MOA): 1) GRM payload delivery, 2) enhanced ADCC and 3) CD19 / BCR signaling inhibition; ABBV-319 demonstrated sustained anti-tumor activity in cell-line xenografts, PDXs and humanized models with superiority to benchmarks; ABBV-319 was well tolerated in GLP toxicities studies and has progressed into Phase 1 clinical testing
  • ||||||||||  prednisone / Generic mfg., dexamethasone injection / Generic mfg.
    Review, Journal:  Factitious cushing's syndrome with unusual presentation: a case report and literature review. (Pubmed Central) -  Aug 9, 2023   
    This case underscores the exceptional rarity of factitious CS and emphasizes the importance of considering it as a potential differential diagnosis in hypercortisolism cases, particularly when the patient's medical history contradicts investigative findings. Furthermore, it highlights the criticality of adopting a multidisciplinary approach to investigate patients whose clinical presentation aligns with factitious CS.
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Journal:  Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma. (Pubmed Central) -  Aug 9, 2023   
    At time of ASCT, patients with IP had significantly increased percentages of CD3CD8CD57 CD28 (P = 0.05) and CD3CD4LAG3 (P = 0.0022) T-cells, as well as less CD56 and CD56 NK cells bearing activated markers such as CD69, NKG2D, and CD226. These data suggest that IP can impact the length of response to ASCT; therefore, further studies on the management of these patients are needed.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Prenatal dexamethasone exposure impaired vascular reactivity in adult male offspring cerebral arteries. (Pubmed Central) -  Aug 9, 2023   
    The combined fluvoxamine treatment did not add benefit in preventing deterioration in patients with mild to moderate COVID-19 without the immunomodulatory effect observed, although it demonstrated low hospitalization rates, oxygen supplemental, intensive care needed, and zero mortality. The present study is the first to demonstrate that the adverse effects of prenatal GCs administration on cerebrovascular tone persist into adulthood, providing new insights into developmental origins of cerebrovascular disease.
  • ||||||||||  methylprednisolone oral / Generic mfg., dexamethasone injection / Generic mfg.
    Trial completion date, Trial primary completion date:  Methylprednisolone Taper, Lower Extremity (clinicaltrials.gov) -  Aug 9, 2023   
    P4,  N=200, Not yet recruiting, 
    The present study is the first to demonstrate that the adverse effects of prenatal GCs administration on cerebrovascular tone persist into adulthood, providing new insights into developmental origins of cerebrovascular disease. Trial completion date: Oct 2023 --> Feb 2024 | Trial primary completion date: Oct 2023 --> Feb 2024
  • ||||||||||  Proair digihaler (albuterol sulfate) / Teva, AirDuo Digihaler (salmeterol/fluticasone proprionate) / Teva
    Trial completion date, Trial primary completion date, Heterogeneity:  Teva Asthma Predictive Analytics Study (clinicaltrials.gov) -  Aug 9, 2023   
    P4,  N=101, Active, not recruiting, 
    Trial completion date: Oct 2024 --> Oct 2025 Trial completion date: Jul 2023 --> Sep 2024 | Trial primary completion date: Jul 2023 --> Sep 2024